New European study will devise ways to reduce the side-effects of radiotherapy
by University of Manchester
Scientists from The University of Manchester are leading a new European study to come up with methods to reduce the unwanted side-effects of radiotherapy and improve cancer treatment.
The research, funded by the European Union and involving 13 institutions in the UK, France, Germany, Belgium, Italy, Spain, The Netherlands and the US, will identify ways to predict which breast, prostate and lung cancer patients are most likely to suffer long-term side effects.
These findings will then be used to design trials that test if cancer treatment can be tailored more specially to individuals so that the worse side effects of radiation – such as bowel or bladder incontinence can be avoided.
There are 17.8million people living in the European Union with a diagnosis of cancer and seven million of these people might receive radiotherapy - a treatment that involves the use of high-energy radiation to kill cancer cells.
In the long-term around 20% of those suffering with mild to severe side-effects – 1.4 million people – could benefit from the improvements the study brings.
Professor Catharine West, Professor of Radiation Biology at The University of Manchester's Institute of Cancer Sciences who is leading the £5million study, said: "Long-term side-effects of radiotherapy impact on the quality-of-life of cancer survivors.
"Earlier work has identified clinical and biological predictors but more work and a better co-ordinated approach is needed to validate these findings so that they can be used in hospitals when treating patients.
"The study, known as REQUITE, aims to develop new clinical models and incorporate biomarkers to identify, before treatment, cancer patients at risk of side-effects. We can then use these models to design interventional trials aimed at reducing side-effects and improving quality of care in cancer survivors who undergo radiotherapy."
The five-year study, which gets underway next month, is the first major grant won by members of the Radiogenomics Consortium, a collaboration set up in 2009 to work on projects identifying the common genetic variations that influence a cancer patient's likelihood of developing side-effects from radiotherapy. REQUITE includes a four year observational study of cancer patients undergoing radiotherapy across Europe, US and in the UK, including The Christie NHS Foundation Trust. Patients will each give a blood sample, from which DNA will be extracted and genotyped to identify genetic variation. Scientists can then look at this variation in terms of the side effects experienced by the patient and use this information to confirm and/or improve current models that try to predict a patient's response to radiotherapy. In the future this type of research could reduce side effects for all radiotherapy patients, improve quality of life and potentially increase the number of patients successfully treated for their cancer.
Professor West, who is also part of the Manchester Cancer Research Centre, a partnership between The University of Manchester, The Christie and Cancer Research UK, added: "Radiotherapy can damage healthy normal tissues which causes side-effects, most are short-lived getting better within a few days or weeks of treatment and might include sore skin, tiredness and hair loss but some can appear months to years following treatment.
"The side-effects can have a long-term impact on quality of life such as if people feel unable to leave their homes for fear of incontinence."
Dr Susan Davidson will run the study at The Christie. Dr Davidson said: "The research will play a role in the long-term goal to make cancer treatment more personalised to individuals. This study should mean that in future doctors can look at a patient's biomarkers by taking a blood test and design their treatment accordingly.
"We will begin recruiting patients to this study when it opens in April 2014."
Professor West added: "This focus on personalised medicine is one of the key things the new Manchester Cancer Research Centre is working hard to do – bringing together a wide range of expertise to revolutionise cancer treatment. By collaborating with specialist partners in Europe and the US, this study we will be the largest of its kind and should provide the clearest picture yet about how different people respond to radiotherapy."
Provided by University of Manchester
Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Despite hype, costly prostate cancer treatment offers little relief from side effects
Accelerated radiotherapy more efficient than current practice
Diabetes drug makes lung cancer vulnerable to radiotherapy
Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy
Carbon ion radiotherapy safe and effective for treating inoperable spinal tumors
New discovery in breast cancer treatment
An unexpected, and novel, target for prostate cancer—our biological clock
Study sheds light on the longstanding question of why cancer cells get their energy from fermentation
New computational method detects disrupted pathways in cancer
Optional (only if you want to be contacted back)
Full version About
Medical Xpress is a web-based medical and health news service that is part of the renowned Science X network. Based on the years of experience as a Phys.org medical research channel, started in April 2011, Medical Xpress became a separate website.
Medical Xpress is a part of Science X network. With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news, the Science X network is one of the largest online communities for science-minded people.
Identify the news topics you want to see and prioritize an order.
Save and exit
Science X Daily and the Weekly Email Newsletters are free features that allow you to receive your favourite sci-tech news updates.
Please, allow us to send you push notifications with new Alerts.
We use cookies to improve your experience on our site
This site uses cookies to assist with navigation, analyse your use of our services, and provide content from third parties.
To find out more, read our Privacy Policy.